# Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

> **NCT00112827** · PHASE1,PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 54 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Smoldering Multiple Myeloma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **RADIATION:** total marrow irradiation
- **DRUG:** melphalan
- **PROCEDURE:** peripheral blood stem cell transplantation
- **BIOLOGICAL:** filgrastim
- **GENETIC:** fluorescence in situ hybridization
- **GENETIC:** cytogenetic analysis
- **DRUG:** cyclophosphamide
- **PROCEDURE:** autologous-autologous tandem hematopoietic stem cell transplantation
- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT00112827
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2019-02-15
- **Final completion:** 2019-02-15
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112827, "Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00112827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*